比较两种不同的放疗加量方法用于前列腺癌患者
不可逆电穿孔放疗增强替代方案与放疗增强治疗中危前列腺癌的比较(IRRADIANT)
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-risk prostate cancer receiving standard stereotactic body radiotherapy (SBRT).
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Jonathan Fainberg, MD, MPH
- 电话号码:646-422-4894
- 邮箱:fainberj@mskcc.org
研究联系人备份
- 姓名:Himanshu Nagar, MD
- 电话号码:212-639-6478
- 邮箱:nagarh1@mskcc.org
学习地点
-
-
New Jersey
-
Basking Ridge、New Jersey、美国、07920
- 招聘中
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
Middletown、New Jersey、美国、07748
- 招聘中
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
Montvale、New Jersey、美国、07645
- 招聘中
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
-
New York
-
Commack、New York、美国、11725
- 招聘中
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
Harrison、New York、美国、10604
- 招聘中
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)
-
接触:
- Himanshu Nager, MD
- 电话号码:212-639-6478
-
New York、New York、美国、10021
- 尚未招聘
- Weill Cornell Medical Center (Data Collection Only)
-
接触:
- Timothy McClure, MD, MS
- 电话号码:(646) 962-6363
-
Uniondale、New York、美国、11553
- 招聘中
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
-
接触:
- Himanshu Nagar, MD
- 电话号码:212-639-6478
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Biopsy proven grade group 2 or 3 (GS 3+4 or GS 4+3) cancer with all pattern 4 found only in the MRI target; systematic biopsy pattern 4 that is concordant with MRI target per investigator is permissible
- Gland size ≤ 80 cc
- Prostate MRI < rT3b disease
- IPSS < 20
- No contraindication to IRE, RT, anesthesia, or transperineal procedure
Exclusion Criteria:
- Any Grade Group ≥4 disease, or any cribriform and/or intraductal carcinoma
- Evidence of nodal or /metastatic disease on MRI and/or PSMA PET/CT
- Unfit for general anesthesia, or contraindication/hypersensitivity to required neuromuscular blocking agents
- Active urinary tract infection (UTI) at the time of IRE or biopsy; must be treated and resolved prior to proceeding
- Actively bleeding, known bleeding disorder, or inability to interrupt anticoagulants/antiplatelet therapy as clinically indicated for biopsy/IRE safety
- Any history of cardiac arrhythmia or epilepsy, or recent myocardial infarction, consistent with NanoKnife contraindication statements
- Presence of an implanted pacemaker/defibrillator or other active implanted electronic device, or other device-related contraindications per current NanoKnife labeling/user manual
- Inability to undergo pelvic MRI
- Prior treatment of prostate cancer including androgen deprivation therapy, focal therapy, radiation therapy, or prostatectomy
- Current or intended use of androgen deprivation therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:IRE Boost Arm
Participants will receive Irreversible Electroporation |
The NanoKnife System is the device that is used for Irreversible Electroporation/IRE. The NanoKnife Generator is a microprocessor-controlled low energy direct current (LEDC) irreversible electroporation device. Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
其他名称:
|
|
有源比较器:RT Boost Arm
Participants will receive Radiation Therapy and will serve as the control arm |
Radiation-based treatment intensification involves delivery of a boost to the dominant intraprostatic lesion (DIL) to a higher dose than the surrounding prostate tissue using external beam radiation therapy.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biopsy negative rate at 2 years
大体时间:2 years
|
The primary objective is to demonstrate that Irreversible Electroporation/IRE boost is non-inferior with respect to negative biopsy rate at 2 years compared to Radiation Therapy/RT boost. This is measured by the two-year biopsy negative rate for the control group and the intervention group. |
2 years
|
合作者和调查者
调查人员
- 首席研究员:Himanshu Nagar, MD、Memorial Sloan Kettering Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 26-029
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.